Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(03): 334-339
DOI: 10.4103/ijmpo.ijmpo_116_17
Original Article

A Study on Utilization and Evaluation of Antiemetics in Chemotherapy‑induced Nausea and Vomiting

Gayathri Baburaj
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangaluru, Karnataka, India
,
Ansha Mariya Abraham
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangaluru, Karnataka, India
,
Lija George
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangaluru, Karnataka, India
,
Vijith Shetty
Department of Oncology, K S Hegde Medical Academy, Nitte University, Mangaluru, Karnataka, India
,
Rovin M Thempalangad
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangaluru, Karnataka, India
,
KS Rajesh
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangaluru, Karnataka, India
,
KC Bharath Raj
Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, Mangaluru, Karnataka, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Purpose: Chemotherapy-induced nausea and vomiting (CINV) are the major adverse effects of cancer chemotherapy. The objectives of this study are to evaluate the utilization of antiemetics in CINV and to assess the emetogenicity of chemotherapy and to investigate the incidence of acute and delayed CINV. Methods: A prospective observational study was carried out in patients undergoing chemotherapy. A suitable data collection form was designed to collect data regarding patient's demographics, cancer type, chemotherapy regimen, antiemetic prescribed, and incidence of CINV according to the standard methods utilizing morrow assessment of nausea and emesis form. Results: Among 200 patients enrolled in the study, with age range of 18–83 (52 ± 11.65; mean ± standard deviation) of both sexes (44% of male and 56% of female), 38.5% of patients received highly emetogenic chemotherapy and 46.5% received moderate emetogenic chemotherapy. Among the patients, 88% received 5HT3-RA in combination with corticosteroid (99%) and NK1-RA (40.5%). Despite the administration of antiemetic, the incidence of acute and delayed nausea after chemotherapy treatment was reported by 54% and 15.5%, respectively. The comparable figures for acute and delayed vomiting were 36.5% and 14.5%. Conclusion: The incidence of CINV among the patients was relatively high and it indicates that more attention is needed for the treatment of both acute and delayed CINV. It also gives an idea for implementation of more efficient antiemesis guideline in the clinical practice.

Keywords

Antiemetics - chemotherapy - nausea - vomiting


Publication History

Article published online:
04 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 American Cancer Society. Cancer Facts and Figures 2017. Atlanta: American Cancer Society; 2017.
  • 2 Bushan K, Cancer Scenario in India. Daily Excelsior.com, 2014. Available from: http://www.dailyexcelsior.com/cancer-scenario-india/. [Last accessed on 2017 Apr 28].
  • 3 Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102.
  • 4 Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000;20:113-21.
  • 5 Manson E, Routledge PA. Nausea and vomiting. In: Walker R, Whittlesia C, editors. Clinical Pharmacy and Therapeutics. 5th ed. China: Churchill Livingstone, Elsevier; 2012. p. 535-44.
  • 6 Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations. Oncologist 2007;12:1143-50.
  • 7 Prevention of chemotherapy-and radiotherapy-induced emesis: Results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 1998;9:811-9.
  • 8 Morrow GR. A patient report measure for the quantification of chemotherapy induced nausea and emesis: Psychometric properties of the Morrow assessment of nausea and emesis (MANE). Br J Cancer Suppl 1992;19:S72-4.
  • 9 Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study. Support Care Cancer 2012;20:107-17.
  • 10 Gilmore JW, Peacock NW, Gu A, Szabo S, Rammage M, Sharpe J, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. J Oncol Pract 2014;10:68-74.
  • 11 Eisenberg P, Vadillo JF, Zamora R, Charu V, Hajdenberg J, Cartmell A, et al. Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Am Cancer Soc 2003;98:2473-82.
  • 12 Sahib AS, Hamdan SJ, Mohammed IH, Khefi AA. Prescribing pattern of antiemetics in the treatment of chemotherapy induced nausea and vomiting. World J Pharm Res 2014;3:3639-54.
  • 13 Zong X, Zhang J, Ji X, Gao J, Ji J. Patterns of antiemetic prophylaxis for chemotherapy-induced nausea and vomiting in China. Chin J Cancer Res 2016;28:168-79.
  • 14 Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Am Cancer Soc 2004;100:2261-8.
  • 15 de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61.